AIA Group Ltd Sells 314,688 Shares of Edwards Lifesciences Corporation $EW

AIA Group Ltd lowered its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 50.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 308,225 shares of the medical research company’s stock after selling 314,688 shares during the quarter. AIA Group Ltd’s holdings in Edwards Lifesciences were worth $23,971,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. JPL Wealth Management LLC bought a new position in Edwards Lifesciences in the third quarter valued at $25,000. True Wealth Design LLC increased its position in shares of Edwards Lifesciences by 251.5% during the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 259 shares during the last quarter. Hantz Financial Services Inc. increased its position in shares of Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 164 shares during the last quarter. Rakuten Securities Inc. raised its holdings in shares of Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after buying an additional 302 shares in the last quarter. Finally, Steigerwald Gordon & Koch Inc. bought a new stake in Edwards Lifesciences in the 3rd quarter worth approximately $30,000. 79.46% of the stock is owned by institutional investors.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total value of $1,103,960.00. Following the completion of the sale, the chief financial officer owned 39,699 shares of the company’s stock, valued at $3,371,239.08. This trade represents a 24.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $85.38, for a total transaction of $87,002.22. Following the completion of the sale, the vice president owned 33,934 shares in the company, valued at approximately $2,897,284.92. This trade represents a 2.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 61,718 shares of company stock worth $5,236,281 over the last quarter. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Down 1.9%

NYSE EW opened at $82.68 on Thursday. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.89. The stock has a market capitalization of $48.02 billion, a PE ratio of 45.18, a PEG ratio of 2.20 and a beta of 0.93. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. The business’s 50-day moving average is $82.32 and its 200 day moving average is $81.63.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The business had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have commented on EW. Wells Fargo & Company increased their price target on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Canaccord Genuity Group set a $87.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Wednesday, December 17th. Citigroup reaffirmed a “buy” rating and issued a $101.00 price objective (up from $96.00) on shares of Edwards Lifesciences in a research note on Thursday, December 11th. BTIG Research reaffirmed a “buy” rating and set a $103.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Finally, Barclays reiterated an “overweight” rating and issued a $104.00 target price (up from $103.00) on shares of Edwards Lifesciences in a research report on Monday, January 12th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $96.14.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.